|4th January 2021||Mark Alan Goldberg||3,452||Grant/award etc.||$4.02||$13,877.04|
|24th December 2020||Mark Alan Goldberg||5,455||Open or private sale||$125.00||$681,875.00|
|24th December 2020||Mark Alan Goldberg||5,455||Exercise of derivative||$28.15||$153,558.25|
|18th December 2020||Mark Alan Goldberg||5,454||Exercise of derivative||$28.15||$153,530.10|
|18th December 2020||Mark Alan Goldberg||5,454||Open or private sale||$120.00||$654,480.00|
|17th December 2020||Charles A Jr Rowland||10,909||Exercise of derivative||$19.53||$213,052.77|
|17th December 2020||Charles A Jr Rowland||10,909||Open or private sale||$117.82||$1,285,298.38|
|14th December 2020||Marion Dorsch||4,600||Exercise of derivative||$37.11||$170,706.00|
|14th December 2020||Jeffrey W. Albers||5,000||Open or private sale||$119.18||$595,900.00|
|14th December 2020||Jeffrey W. Albers||5,000||Exercise of derivative||$8.80||$44,000.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Blueprint Medicines Corp. focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy in 2008.